A phase III, open-label, multicenter flexible dose, long-term (52 weeks) safety and efficacy study of an investigational drug in the treatment of schizophrenia

The primary objective of this study is to determine if flexible doses of an investigational drug are safe in the long-term treatment of subjects with schizophrenia. The secondary objective is to assess the maintenance of efficacy of an investigational drug in treating schizophrenia.

You may be eligible to participate in this study if you:

• Are between 18-75 years of age
• Have a primary diagnosis of schizophrenia
• Are in stable physical health

You will be excluded from this study if you have:

• A significant risk of suicide and/or violent behavior
• A current diagnosis or history of substance or alcohol abuse

This is a partial list of eligibility and exclusion criteria. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.